Acta NaturaeActa NaturaeActa Naturae2075-8251Acta Naturae Ltd1074810.32607/20758251-2010-2-3-21-29ArticlesСтатьиReview ArticleToll-Like Receptors (TLRs): The Role in Tumor ProgressionToll-Like Receptors (TLRs): The Role in Tumor ProgressionShchebliakovD VLogunovD Yldenisy@yahoo.comTukhvatulinA IShmarovM MNaroditskyB SGinzburgA LGamaleya Research Institute of Epidemiology and Microbiology, Russian Academy of Medical Sciences1509201023VOL 2, NO3 (2010)ТОМ 2, №3 (2010)212917012020Copyright ©; 2010, Shchebliakov D.V., Logunov D.Y., Tukhvatulin A.I., Shmarov M.M., Naroditsky B.S., Ginzburg A.L.Copyright ©; 2010, Shchebliakov D.V., Logunov D.Y., Tukhvatulin A.I., Shmarov M.M., Naroditsky B.S., Ginzburg A.L.2010Shchebliakov D.V., Logunov D.Y., Tukhvatulin A.I., Shmarov M.M., Naroditsky B.S., Ginzburg A.L.Shchebliakov D.V., Logunov D.Y., Tukhvatulin A.I., Shmarov M.M., Naroditsky B.S., Ginzburg A.L.https://creativecommons.org/licenses/by/4.0https://actanaturae.ru/2075-8251/article/view/10748

Toll-like receptors (TLRs) are major components of the innate immune system that recognize the conserved molecular structures of pathogens (pathogen-associated molecular patterns; PAMPs). TLRs are found omega seamaster midsize replica in many different cell types, ranging from epithelial to immunocompetent cells. TLR binding triggers the expression of several adapter proteins and downstream kinases, leading to the induction of key pro-inflammatory mediators. This results in the activation of both the innate immune response (elevated expression of antiapoptotic proteins, proinflammatory cytokines, and antibacterial proteins), as well as the adaptive immune response (maturation of the dendritic cells, antigen presentation, etc.). In consequence of their ability to enhance the specific and nonspecific immune reactions of an organism, TLR agonists are widely used in the therapy of infectious diseases and, as adjuvants, in the therapy of malignant neoplasia. However, to date, rolex imitation jewellery TLRs have had the opposite effects on tumor progression. On the one hand, TLR ligands can suppress tumor growth. On the other hand, TLR agonists can promote the survival of malignant cells and increase their resistance to chemotherapy. The purpose of this review is to summarize the available data on the effects of TLRs and their agonists on tumor progression, as well as the mechanisms underlying the differences in the effects of best replica watches sites 2020TLRs on tumor growth.

toll-like receptorsagonists of innate immune receptorstumor progressioninnate immune responseinflammationCoussens L.M., Werb Z. // Nature. 2002. V. 420(6917). P. 860-867.Mantovani A., Allavena P., Sica A., Balkwill F. // Nature. 2008. V. 454(7203). P 436-444.Okamoto T. // Endocr. Metab. Immune Disord. Drug. Targets. 2006. V. 6(4). P. 359-372Thomas H.G., Han J.H., Balentien E., et al. // Methods Enzymol. 1991. V. 198. P 373-383.Kleeff J., Kusama T., Rossi D.L. // Int. J. Cancer. 1999. V. 81. P. 650-657.Deveraux Q.L., Schendel S.L., Reed J.C. // Cardiol. Clin. 2001. V. 19(1). P. 57-74.Dong Z., Wang J.Z., Yu F., Venkatachalam M.A. // Am. J. Pathol. 2003. V. 163(2). P. 663-671.Bartsch H., Nair J. // Langenbecks Arch. Surg. 2006. V. 391(5). P 499-510.Moser B., Willimann K. // Ann. Rheum. Dis. 2004. V. 63 Suppl 2. P. 84-89.Rasmussen S.B., Reinert L.S., Paludan S.R. // APMIS. 2009. V. 117(5-6). P. 323-337.Palm N.W., Medzhitov R. // Immunol. Rev. 2009. V. 227(1). P. 221-233.Zeromski J., Mozer-Lisewska I., Kaczmarek M. // Cancer Microenviron. 2008. V. 1(1). P 37-42.Jego G., Bataille R., Geffroy-Luseau A., et al. // Leukemia. 2006. V. 20(6). P. 1130-1137.Seya T., Akazawa T., Uehori J., et al. // Anticancer Res. 2003. V. 23(6a). P. 4369-4376.Grauer O.M., Molling J.W., Bennink E., et al. // J. Immunol. 2008. V. 15. P. 6720-6729.Medzhitov R. // Nat. Rev. Immunol. 2001. V. 1(2). P. 135-145.Pasare C., Medzhitov R. // Nature. 2005. V. 438(7066). P. 364-368.Zasloff M. // Nature. 2002. V. 415(6870). P 389-395.Doyle S.E., O‘Connell R.M., Miranda G.A., et al. // J. Exp. Med. 2004. V. 5. P. 81-90.Werling D., Hope J.C., Howard C.J., Jungi T.W. // Immunology. 2004. V. 111(1). P 41-52.Nijhuis M.M., Pasterkamp G., Sluis N.I., et al. // J. Vasc. Res. 2007. V. 44(3). P. 214-222.Kaisho T., Akira S. // J. Allergy Clin. Immunol. 2006. V. 117(5). P. 979-988.Salaun B., Romero P., Lebecque S. // Eur. J. Immunol. 2007. V. 37(12). P 3311-3318.Iwasaki A., Medzhitov R. // Nat. Immunol. 2004. V. 5(10). P. 987-995.Pasare C., Medzhitov R. // Adv. Exp. Med. Biol. 2005. V. 560. P. 11-18.Li M., Zhou Y., Feng G., Su S.B. // Curr. Mol. Med. 2009. V. 9(3). P. 365-374.Curtiss L.K., Tobias P.S. // J. Lipid. Res. 2009. V. 50 Suppl. P. 340-345.Krieg A.M. // J. Clin. Invest. 2007. V. 117. P 1184-1194.Chicoine M.R., Zahner M., Won E.K. // Neurosurgery. 2007. V. 60. P. 372-381.Harmey J.H., Bucana C.D., Lu W. // Int. J. Cancer. 2002. V. 101. P. 415-422.Huang B., Zhao J., Shen S. // Cancer. Res. 2007. V. 67. P. 4346-4352.Means T.K., Golenbock D.T., Fenton M.J. // Life Sci. 2000. V. 8. P. 241-258.Diebold S.S. // Handb. Exp. Pharmacol. 2009. V. 188. P. 3-30.West A.P., Koblansky A.A., Ghosh S.// Annu Rev. Cell. Dev. Biol. 2006. V. 22. P. 409-437.Zhang Z., Schluesener H.J. // Cell Mol. Life Sci. 2006. V. 63(24). P. 2901-2907.O‘Neill L.A., Bowie A.G. // Nat. Rev. Immunol. 2007. V. 7(5). P. 353-364.Stockfleth E., Trefzer U., Garcia-Bartels C. // Br. J. Dermatol. 2003. V. 149 (Suppl. 66). P. 53-56.Nogueras S., Merino A., Ojeda R. // Heart. Circ. Physiol. 2008. V. 294. P 708-713.Okamoto M., Oshikawa T., Tano T., et al. // J. Immunother. 2006. V. 29. P. 78-86.D‘Agostini C., Pica F., Febbraro G., et al. // Int. Immunopharmacol. 2005. V. 5(7-8). P 1205-1212.Morales A., Eidinger D., Bruce A.W. // J. Urol. 1976. V. 116. P. 180-183.Street S.E., Cretney E., Smyth M.J. // Blood. 2001. V. 1; 97(1). P. 192-197.Swann J.B., Hayakawa Y., Zerafa N., et al. // J. Immunol. 2007. V. 15;178(12). P 7540-7549.Martinez F.O., Sica A., Mantovani A., et al. // Front. Biosci. 2008. V. 13. P. 453-461.Balkwill F., Coussens L.M. // Nature. 2004. V. 431. P 405406.Robak P, Smolewski P, Robak T. // Leuk. Lymphoma. 2008. V. 49. P. 1452-1462.Pikarsky E., Porat R.M., Stein I., et al. // Nature. 2004. V. 431. P 461-466.Palayoor S.T., Youmell M.Y., Calderwood S.K., et al. // Oncogene. 1999. V. 18. P. 7389-7394.Griffin J.D. // Blood. 2001. V. 98. P 2291.Philip M., Rowley D.A., Schreiber H. // Semin. Cancer Biol. 2004. V. 14. P. 433-439.Swann J.B., Vesely M.D., Silva A., et al. // Proc. Natl. Acad. Sci. USA. 2008. V. 105. P 652-656.Shcheblyakov D.V., Logunov D.Yu, Zubkova O.V., et al. // Mol. Genetika, mikrobiol. i virusol. ( Mol. Genet. Microbiol. Virol.). 2008. N 4. P 163-167.Logunov D., Scheblyakov D., Zubkova O., et al. // Oncogene. 2008. V. 27. P. 4521-4531.Kim S., Takahashi H., Lin W.W., et al. // Nature. 2009. V. 457. P 102-106.Luo J.L., Maeda S., Hsu L.C., et al. // Cancer Cell. 2004. V. 6. P. 297-305.Huang B., Zhao J., Li H. // Cancer Res. 2005. V. 65. P. 50095014.Kim W.Y., Lee J.W., Choi J.J., et al. // Int. J. Gynecol. Cancer. 2008. V. 18. P. 300-305.Droemann D., Albrecht D., Gerdes J., et al. // Respir. Res. 2005. V. 6. P 1-6.Ilvesaro J.M., Merrell M.A., Swain T.M., et al. // Prostate. 2007. V. 67. P 774-781.Lotze M.T., Zeh H.J., Rubartelli A., et al. // Immunol. Rev. 2007. V. 220. P. 60-81.Ellerman J.E., Brown C.K., Vera M., et al. // Clin. Cancer Res. 2008. V. 13. P. 2836-2848.Cabezon T., Celis J.E., Skibshoj I., et al. // Int. J. Cancer. 2007. V. 121. P 1433-1444Adams S., O‘Neill D.W., Nonaka D., et al. // J. Immunol. 2008. V. 181. P. 776-784.Spaner D.E., Miller R.L., Mena J., et al. // Leuk. Lymphoma. 2005. V. 46. P 935-939.Dudek A.Z., Yunis C., Harrison L.I., et al. // Clin. Cancer Res. 2007. V. 13. P 7119-7125.Schmidt J., Welsch T., Jager D., et al. // Br. J. Cancer. 2007. V. 97. P 598-604.Karin M., Yamamoto Y., Wang Q.M. // Nat. Rev. Drug. 2004. V. 3. P 17-26.